Stereotaxis, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US85916J4094
USD
2.43
0.1 (4.29%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Stereotaxis, Inc. stock-summary
stock-summary
Stereotaxis, Inc.
Pharmaceuticals & Biotechnology
Stereotaxis, Inc. is a United States-based healthcare technology company. The Company is engaged in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease. The Company also provides information management solutions for the interventional lab. The Stereotaxis platform helps physicians to provide patient care with robotic precision and enhanced integration of procedural information. The Company’s Epoch solution includes the Niobe ES remote magnetic navigation system, the Odyssey portfolio of lab optimization, networking and patient information management systems, and the Vdrive robotic navigation system and consumables. The Niobe ES remote magnetic navigation system includes the Navigant software user interface and the QuikCAS catheter advancement system. The Vdrive robotic navigation system with Niobe ES magnetic navigation system provides navigation and stability for diagnostic and ablation devices.
Company Coordinates stock-summary
Company Details
4320 Forest Park Ave Ste 100 , ST. LOUIS MO : 63108-2979
stock-summary
Tel: 1 314 6786100
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 16 Schemes (9.44%)

Foreign Institutions

Held by 27 Foreign Institutions (1.43%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. David Fischel
Chairman of the Board, Chief Executive Officer
Mr. David Benfer
Lead Independent Director
Dr. Nathan Fischel
Director
Mr. Joseph Kiani
Independent Director
Mr. Ross Levin
Independent Director
Dr. Arun Menawat
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
9 Million
(Quarterly Results - Jun 2025)
Net Profit:
-4 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 262 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.94

stock-summary
Return on Equity

-345.88%

stock-summary
Price to Book

38.85